Consent given pursuant to Sections 14 and 14A to the importation and supply of the therapeutic goods specified by Biogen Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide a legislative framework for the regulation of therapeutic goods in Australia, addressing the need for a unified approach to the control and oversight of such products. This Act was established by the Australian Parliament to ensure that therapeutic goods available in the market are safe, of high quality, and effective. The 1989 Act was designed to fill the gap in comprehensive regulation across various types of therapeutic goods, including medicines, medical devices, and blood products. The policy objective behind the Act is to protect public health by ensuring that therapeutic goods meet appropriate standards and are properly monitored throughout their lifecycle. The Therapeutic Goods Administration, as the executive arm of the Department of Health, plays a critical role in implementing and enforcing the provisions of the Act. In December 2015, the Therapeutic Goods Administration granted a consent under sections 14 and 14A of the Act to Biogen Australia Pty Ltd for the importation and supply of specific batches of dimethyl fumarate (TECFIDERA) modified release capsules. This consent allowed for the temporary importation and supply of products that did not fully comply with the label requirements outlined in the Therapeutic Goods Order No. 69. Specifically, the consent permitted the use of carton labels that included the sponsor’s old address and/or name. The consent was effective from 11 December 2015 until the nominated batches were exhausted or expired, and it was subject to certain conditions to mitigate any potential risks associated with the non-compliant labels.

Scope and Application

The Therapeutic Goods Act 1989 applies to a wide range of therapeutic goods, including medicines, medical devices, and blood and blood components. It governs the regulation and oversight of these products to ensure they are safe, of high quality, and effective. The Act applies to individuals and entities involved in the manufacture, supply, and importation of therapeutic goods, as well as to the conduct and transactions related to these goods. The geographic reach of the Act is national, as it applies across the Commonwealth of Australia. The Act may extend its application through subordinate instruments, such as therapeutic goods regulations and orders. There may be stated exclusions, exemptions, or thresholds within these subordinate instruments, but the primary Act itself broadly applies to all therapeutic goods within Australia. The consent provided under sections 14 and 14A of the Act allows for certain products to be imported and supplied despite not fully conforming to the labelling requirements, subject to specific conditions.

Key Provisions

Under sections 14 and 14A of the Therapeutic Goods Act 1989, a delegate of the Secretary of the Department of Health granted Biogen Australia Pty Ltd consent to import and supply specific batches of dimethyl fumarate (TECFIDERA) 120 mg and 240 mg modified release capsules blister packs that do not comply with certain labelling requirements (sections 14(1), 14A(1)). This consent allows the importation and supply of these products despite the non-compliance with the Therapeutic Goods Order No. 69, specifically paragraph 3(2)(l) concerning the carton labels which include the sponsor’s old address and/or name. The consent is limited in scope and duration, being effective from 11 December 2015 until the nominated batches are exhausted or expired. The obligations imposed by this consent on Biogen Australia Pty Ltd include ensuring that the carton labels used for the specified batches are those that are currently approved for use. This means that any labelling that does not meet the specified requirements is not permitted and must be replaced with the correct labels as soon as possible. Additionally, Biogen Australia Pty Ltd must adhere to the conditions outlined in the consent, which primarily revolve around the use of approved carton labels to mitigate any potential risks associated with the non-compliant labels. Failure to comply with the conditions of the consent may result in legal consequences. While the specific offences and penalties are not detailed in the provided text, breaches of the Therapeutic Goods Act 1989 can typically lead to both civil and criminal penalties. Civil penalties may include fines, and in more severe cases, criminal penalties such as imprisonment can be imposed. The exact penalties depend on the nature and severity of the breach, but they are intended to enforce compliance with therapeutic goods regulations to protect public health and safety. In summary, the Therapeutic Goods Act 1989, through sections 14 and 14A, provides a mechanism for granting consent to import and supply therapeutic goods that do not fully comply with certain regulatory requirements, subject to specific conditions. Biogen Australia Pty Ltd’s consent to import and supply the specified batches of TECFIDERA capsules is contingent on the use of currently approved carton labels. Non-compliance with the conditions of this consent may result in significant legal repercussions, reinforcing the importance of adhering to regulatory standards within the therapeutic goods industry.